Sandu Pharmaceuticals News

Sandu Pharma Reports No Fund Deviation in Q3 FY26

Sandu Pharmaceuticals Limited filed its quarterly statement confirming no deviation in utilization of funds raised through preferential issue across three tranches for Q3 FY26 ended December 31, 2025.

Sandu Pharmaceuticals Board Meet on Feb 6, 2026

Sandu Pharmaceuticals Limited has scheduled a board meeting on February 06, 2026, to approve Q3FY26 unaudited financial results for the quarter ended December 31, 2025.

Sandu Pharma Gets GST Notice for ₹13L Discrepancy

Sandu Pharmaceuticals receives GST notice from Maharashtra authorities regarding ₹13.00 lakh discrepancy in ITC reversal for FY2023-24. Company expects favorable outcome.

Sandu Pharmaceuticals Shareholders Approve Reclassification of Akshath Finvest from Promoter to Public Category

Sandu Pharmaceuticals Limited received shareholder approval through postal ballot to reclassify Akshath Finvest and Properties Private Limited from promoter/promoter group to public category, involving 4,94,182 shares representing 5.12% shareholding. The resolution was passed with 92.02% votes in favor, reducing promoter shareholding from 42.90% to 37.79% and increasing public shareholding from 57.10% to 62.21%.